A new study has found something that pharmaceutical companies are unlikely to advertise: women who lost significant weight while taking GLP-1 medications such as Ozempic or Wegovy were hired for jobs at higher rates after treatment than before — a finding that researchers say reflects not a treatment success, but a symptom of a deeply entrenched and largely unaddressed form of workplace discrimination.
The findings arrive as GLP-1 drug use among women of working age is rapidly expanding, fueled by Medicare's new coverage program, growing commercial insurance availability, and direct-to-consumer marketing that increasingly frames these medications as transformative not just medically but socially. The employment benefit documented in the study appears real. But the mechanism behind it is not improved health — it is reduced weight bias from employers.
